Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Nov 10, 2014

Lytix Biopharma was represented by Øystein Rekdal (CSO Oncology) at SITC (the Society for Immunotherapy of Cancer) meeting 2014.

Saturday November 8th, the company presented a poster (P264) showing the effect of LTX-315 on both treated and non-treated lesions in a rat sarcoma model. The title of the poster is: “Complete and specific regression of disseminated tumors in a novel rat mesenchymal three-tumor model after intralesional treatment with the nonapeptide LTX-315 (OncoporeTM)

See the poster